Cancer drug shows promise but study halted early
NCT ID NCT04042714
First seen Nov 05, 2025 · Last updated May 10, 2026 · Updated 22 times
Summary
This study tested the drug TAS-102 in 14 people with a rare and aggressive type of cancer called high-grade neuroendocrine cancer that started outside the lungs. The goal was to see if the drug could shrink tumors and improve survival. The study was stopped early, so results are limited, but researchers hoped TAS-102 might offer a new treatment option for this hard-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE EXTRA PULMONARY NEUROENDOCRINE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor Scott and White University Medical Center,
Dallas, Texas, 75246, United States
Conditions
Explore the condition pages connected to this study.